A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

Table 2

Locations of metastases and responses after two courses of GN therapy.

	CR⋅PR	SD	PD	Total
Lymph node	13 (59%)	7	2	22
Lung	4 (57%)	1	2	7
Liver	2 (67%)	1	0	3
Bone	0 (0.0%)	2	0	2
Local recurrence	1 (17%)	5	0	6
Urethra	0 (0.0%)	1	0	1